Compare AGNC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGNC | EXEL |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | United States |
| Employees | 54 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 11.7B |
| IPO Year | N/A | 2000 |
| Metric | AGNC | EXEL |
|---|---|---|
| Price | $10.22 | $41.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | $11.03 | ★ $46.45 |
| AVG Volume (30 Days) | ★ 16.9M | 2.8M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 13.86% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | N/A | $13.66 |
| Revenue Next Year | $0.51 | $13.73 |
| P/E Ratio | ★ $7.69 | $14.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $32.38 |
| 52 Week High | $12.19 | $48.74 |
| Indicator | AGNC | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 27.17 | 42.55 |
| Support Level | $9.85 | $40.01 |
| Resistance Level | $10.32 | $44.15 |
| Average True Range (ATR) | 0.24 | 1.33 |
| MACD | -0.09 | -0.16 |
| Stochastic Oscillator | 0.43 | 26.06 |
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.